维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

共被期刊论文引用了1次 您的检索式：您选中1篇文献正在查看引证文献汇总

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Development of NT3 Genetically Engineered cells using human Lymphocytes显示文摘Objective To establish a lymphocyte line capable of long survival and expressing human NT-3 to lay a foundation for future animal and human cochlear gene transfection research. Methods We collected lymphocytes from normal human blood via Ficoll fluid and added IL-2 into the serum culture medium to promote lymphocyte growth. The NT3 cDNA was obtained by RT-PCR and ligated with the eukaryon vector which is pIRES-DsRed2 using T4DNA enzyme. The NT3 cDNA gene was transfected into the lymphocyte line using cationic liposome (LP2000). The lymphocytes transfected with NT3-cDNA were examined by RT-PCR and Western-blot methods. Results We established a new method to extend in vitro lymphocytes survival time and to transfect NT3 into lymphocytes. The genetically engineered lymphocytes were capable of surviving over relatively long time. Positive protein signals were obtained by Western blot. Conclusions Using lymphocytes as the intermediary, recombined plasmid pIRES-DsRed2NT3 is used to establish a lymphocyte line that expresses and secretes NT3. This cell line can be used in future animal gene cochlear transfection research and may help find an intermediary cell line for gene therapy for human deafness.	MA Xiao-feng1, XU Lin1, CHEN Jie1, LU Ling1, GAO Xia1 1 Department of Otolaryngology & Head and Neck Surgery, the affiliated Drum Tower Hospital of Nanjing University Medical College, Jiangsu 210008, China	2010	Journal of Otology2010，5，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费